2US Stock Overview
A clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NextCure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$2.28 |
| 52 Week Low | US$1.00 |
| Beta | 0.79 |
| 11 Month Change | -8.28% |
| 3 Month Change | -19.29% |
| 1 Year Change | 2.73% |
| 33 Year Change | -78.41% |
| 5 Year Change | -97.07% |
| Change since IPO | -93.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2US | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.3% | 0.8% | 0.8% |
| 1Y | 2.7% | -18.3% | 8.6% |
Return vs Industry: 2US exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 2US underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 2US volatility | |
|---|---|
| 2US Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2US's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2US's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 82 | Michael Richman | www.nextcure.com |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules.
NextCure, Inc. Fundamentals Summary
| 2US fundamental statistics | |
|---|---|
| Market cap | €32.08m |
| Earnings (TTM) | -€55.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 2US overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2US income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$58.52m |
| Earnings | -US$58.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2US perform over the long term?
See historical performance and comparison